$FMHS
FARMHOUSE, INC. /NV Stock $fmhs

$fmhs Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000109690624001512 Filed on July 11, 2024

Income Statement

Concept	2024 Q3	2023 Q4	2023
Revenue		$4.520K	$15.23K
YoY Change		71.21%	48.4%
Cost Of Revenue		$1.920K	$6.930K
YoY Change		45.45%	82.08%
Gross Profit		$2.600K	$8.297K
YoY Change		96.97%	28.54%
Gross Profit Margin		57.52%	54.49%
Selling, General & Admin		$109.4K	$517.8K
YoY Change		-22.47%	-34.1%
% of Gross Profit		4207.69%	6241.29%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$0.00	$0.00
YoY Change			-100.0%
% of Gross Profit		0.0%	0.0%
Operating Expenses		$109.4K	$517.8K
YoY Change		-22.47%	-34.12%
Operating Profit		-$106.8K	-$509.5K
YoY Change		-23.6%	-34.64%
Interest Expense		-$13.24K	$51.24K
YoY Change		-106.23%	-3.59%
% of Operating Profit
Other Income/Expense, Net			-$51.24K
YoY Change			-115.21%
Pretax Income		-$120.0K	-$560.8K
YoY Change		-265.39%	26.65%
Income Tax			$0.00
% Of Pretax Income
Net Earnings		-$120.0K	-$560.8K
YoY Change		-265.39%	26.65%
Net Earnings / Revenue		-2655.75%	-3682.86%
Basic Earnings Per Share
Diluted Earnings Per Share		-$0.01	-$0.03
COMMON SHARES
Basic Shares Outstanding	17.73M shares	17.33M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash & Equivalents	$0.00	$0.00
Short-Term Investments
Other Short-Term Assets	$3.990K	$3.990K
YoY Change	4.72%	4.72%
Inventory
Prepaid Expenses	$3.990K
Receivables	$4.170K	$4.170K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$8.160K	$8.160K
YoY Change	-87.61%	-87.61%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$8.160K	$8.160K
Total Long-Term Assets	$0.00	$0.00
Total Assets	$8.160K	$8.160K
YoY Change	-87.61%	-87.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$45.44K	$45.44K
YoY Change	306.36%	306.44%
Accrued Expenses	$204.1K	$1.783M
YoY Change	30.76%	18.97%
Deferred Revenue
YoY Change
Short-Term Debt	$95.00K	$95.00K
YoY Change	0.0%	0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.952M	$1.952M
YoY Change	18.34%	18.35%
LONG-TERM LIABILITIES
Long-Term Debt	$34.00K	$34.00K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$34.00K	$34.00K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.952M	$1.952M
Total Long-Term Liabilities	$34.00K	$34.00K
Total Liabilities	$1.986M	$1.986M
YoY Change	20.41%	20.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.305M
YoY Change	9.76%
Common Stock	$1.733K
YoY Change	1.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.978M	-$1.978M
YoY Change
Total Liabilities & Shareholders Equity	$8.160K	$8.160K
YoY Change	-87.61%	-87.61%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$120.0K	-$560.8K
YoY Change	-265.39%	26.65%
Depreciation, Depletion And Amortization	$0.00	$0.00
YoY Change		-100.0%
Cash From Operating Activities	-$13.54K	-$83.45K
YoY Change	33.4%	-66.99%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.380K	$21.39K
YoY Change	-103.12%	-127.1%
NET CHANGE
Cash From Operating Activities	-13.54K	-$83.45K
Cash From Investing Activities	0.000	$0.00
Cash From Financing Activities	8.380K	$21.39K
Net Change In Cash	-5.160K	-$62.06K
YoY Change	-90.45%	-206.49%
FREE CASH FLOW
Cash From Operating Activities	-$13.54K	-$83.45K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	333-238326
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3321759
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	548 Market Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 90355
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94104
CY2023	dei	Entity Address Address Description EntityAddressAddressDescription	Address of principal executive offices
CY2023	dei	Phone Fax Number Description PhoneFaxNumberDescription	Registrant’s telephone number
CY2023	dei	City Area Code CityAreaCode	888
CY2023	dei	Local Phone Number LocalPhoneNumber	420-6856
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2925000	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17728450	shares
CY2023	dei	Auditor Firm AuditorFirmId	6258
CY2023	dei	Auditor Name AuditorName	Mac Accounting Group & CPAs, LLP
CY2023	dei	Auditor Location AuditorLocation	Midvale, Utah
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62063	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4170	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3990	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3810	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	8160	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	65873	usd
CY2023Q4	us-gaap	Assets Assets	8160	usd
CY2022Q4	us-gaap	Assets Assets	65873	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	45435	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11181	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	387501	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	348137	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1129752	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	945608	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	204050	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	156050	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	61745	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	48931	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	50000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	50000	usd
CY2023Q4	fil	Due To Related Parties1 DueToRelatedParties1	28958	usd
CY2022Q4	fil	Due To Related Parties1 DueToRelatedParties1	44882	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1952441	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1649789	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	34000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	34000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1986441	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1649789	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17325950	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17325950	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17075950	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17075950	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1733	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1708	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4325474	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4159075	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6305488	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5744699	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1978281	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1583916	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8160	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65873	usd
CY2023	us-gaap	Revenues Revenues	15227	usd
CY2022	us-gaap	Revenues Revenues	10261	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	6930	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3806	usd
CY2023	us-gaap	Gross Profit GrossProfit	8297	usd
CY2022	us-gaap	Gross Profit GrossProfit	6455	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	336092	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	403372	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	181751	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	382371	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	94	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	250	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	517843	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	786087	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-509546	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-779632	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	165000	usd
CY2023	us-gaap	Net Investment Income NetInvestmentIncome	0	usd
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	225000	usd
CY2023	us-gaap	Interest Expense InterestExpense	51243	usd
CY2022	us-gaap	Interest Expense InterestExpense	53150	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-51243	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	336850	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-560789	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-442782	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-560789	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-442782	usd
CY2023	fil	Basic And Diluted Net Loss Per Share BasicAndDilutedNetLossPerShare	-0.03
CY2022	fil	Basic And Diluted Net Loss Per Share BasicAndDilutedNetLossPerShare	-0.03
CY2023	fil	Basic And Diluted Weighted Average Number Of Shares Outstanding BasicAndDilutedWeightedAverageNumberOfSharesOutstanding	17130160	shares
CY2022	fil	Basic And Diluted Weighted Average Number Of Shares Outstanding BasicAndDilutedWeightedAverageNumberOfSharesOutstanding	16376154	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1571243	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	59415	usd
CY2022	fil	Common Stock Issued For Restricted Stock Awards CommonStockIssuedForRestrictedStockAwards	0	usd
CY2022	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	181112	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	189582	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-442782	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1583916	usd
CY2023	fil	Common Stock Issued For Restricted Stock Awards CommonStockIssuedForRestrictedStockAwards	0	usd
CY2023	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	166424	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-560789	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1978281	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-560789	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-442782	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	94	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	189582	usd
CY2023	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	166424	usd
CY2022	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	181112	usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	250	usd
CY2023	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	0	usd
CY2022	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	225000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	165000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4170	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	180	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	60	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	30939	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-16421	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	39364	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-42930	usd
CY2023	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	184144	usd
CY2022	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	184145	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	48000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	55254	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	12814	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	10861	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83454	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-270895	usd
CY2023	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	0	usd
CY2022	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	165000	usd
CY2023	fil	Settlement From Equity Security Investment SettlementFromEquitySecurityInvestment	0	usd
CY2022	fil	Settlement From Equity Security Investment SettlementFromEquitySecurityInvestment	225000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	390000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	59415	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	7620	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	34000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	10761	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	32650	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	23370	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	95207	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21391	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-60822	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-62063	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	58283	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62063	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3780	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62063	usd
CY2023	fil	Repayment Of Related Party Short Term Advances With Credit Card RepaymentOfRelatedPartyShortTermAdvancesWithCreditCard	3315	usd
CY2022	fil	Repayment Of Related Party Short Term Advances With Credit Card RepaymentOfRelatedPartyShortTermAdvancesWithCreditCard	18102	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1253	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font:11pt Times New Roman;margin:0;margin-right:-1.8pt"><b>NOTE 1 – ORGANIZATION AND OPERATIONS</b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Organization</i></b></p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF"> </p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF">The Company was incorporated in June 2013 as Somerset Transition Corporation under the Oklahoma General Corporation Act. In September 2013, the Company was redomesticated in Maryland and changed its name to Somerset Property, Inc. In July 2017, the Company was redomesticated in Nevada and changed its name to Revival, Inc. In June 2019, the Company changed its name to Farmhouse, Inc. to reflect its new business endeavors. </p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF"> </p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF">In August 2019, the Company acquired Farmhouse, Inc., a Washington corporation (“Farmhouse Washington”) as its wholly owned subsidiary (the “Acquisition”). The financial statements of the Company are the continuation of Farmhouse Washington with the adjustment to reflect the capital structure of the Company. The consolidated financial statements also includes Farmhouse DTLA, Inc., a wholly owned subsidiary of Farmhouse Washington (“DTLA”). DTLA is party to certain litigation. See Note 9.</p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF"> </p> <p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Current Operations</i></b></p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF"> </p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF">The Company is a technology company with multiple cannabis related divisions and IP, including the WeedClub® Platform, the @420 Twitter handle and a Web3 division. The WeedClub® Platform is a cannabis social network platform that enables industry professionals to connect, discover products and services and scale their businesses. Within the WeedClub® Platform, members utilize an increasing set of technology-based tools for discovering professional connections and information. The Company’s @420 Twitter handle serves as a public platform to engage with cannabis enthusiasts. The Company’s Web3 division, launched in December 2021, facilitates licensing opportunities between established cannabis brands and influential digital collectible holders to launch digital collectible branded products and accessories.</p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF"> </p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF">Subsequent to December 31, 2023, the Company executed a non-binding Memorandum of Understanding for a proposed acquisition of all membership interests of Thrown, LLC, a joint venture beverage firm led by T-Pain, the Grammy Award-winning artist, professional gamer, and entrepreneur. Thrown’s premier product, T-Pain’s GamerShot, is a zero-crash, focus-enhancing functional esports beverage, featuring a proprietary Nootropic Energy Blend and conveniently packaged in 2-ounce servings. See Note 14.</p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF"> </p> <p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Going Concern and Management Plans</i></b></p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF"> </p> <p style="font:11pt Times New Roman;margin:0;margin-right:-4.5pt;background-color:#FFFFFF">The accompanying consolidated financial statements have been presented on the basis that the Company is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. For the year ended December 31, 2023, the Company had a net loss from operations of $509,546, consisting of general and administrative and legal and professional expenses. In addition, as of December 31, 2023, the Company had stockholders’ deficit of $1,978,281. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF"> </p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF">The Company has financed its activities principally from the sale of its common stock, loans and advances from Company officers, and loans from third parties. The Company intends to finance its future working capital needs from these sources until such time that funds provided by operations are sufficient </p> <p style="font:11pt Times New Roman;margin:0;background-color:#FFFFFF">to fund working capital requirements. Management believes that loans and advances from Company officers, funds raised from the sale of its common stock, and funds raised from loans with third parties allow the Company sufficient capital for operations and to continue as a going concern.</p>
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-509546	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1978281	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Financial Statement Reclassification</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">Certain amounts from the prior year’s financial statements have been reclassified in these consolidated financial statements to conform to the current year’s classifications.</p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Use of Estimates</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of revenue and expenses for the reporting period. Actual results could differ from those estimates.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font:11pt Times New Roman;margin:0;text-indent:36pt"><b><i>Concentrations of Credit Risk</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable as of December 31, 2023. The Company places its cash with high credit quality financial institutions. </p>
CY2023	us-gaap	Revenues Revenues	15227	usd
CY2022	us-gaap	Revenues Revenues	10261	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	6930	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3806	usd
CY2023	us-gaap	Concentration Risk License ConcentrationRiskLicense	A new licensee accounted for 91.0% of license revenues
CY2022	us-gaap	Concentration Risk License ConcentrationRiskLicense	Two licensees represented 60.4% and 39.6% of license revenues
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2023Q4	fil	Company S Series2023 Notes Excluded From Dilutive Net Income Loss Per Common Share CompanySSeries2023NotesExcludedFromDilutiveNetIncomeLossPerCommonShare	34000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	45000	usd
CY2023	fil	Equity Financing Description EquityFinancingDescription	The note and any unpaid accrued interest automatically converts in whole upon a qualified financing which is defined as an equity financing resulting in gross proceeds to the Company of at least $750,000 (including the conversion of the Notes and other debt). The conversion price would be equal to 100% of the per share price paid in the qualified financing, provided that: if the Company valuation associated with the Qualified Financing is less than $15,000,000, the valuation associated with the conversation shall be $15,000,000; and, if the Company valuation associated with the Qualified Financing is greater than $30,000,000, the Company valuation associated with the conversion shall be $30,000,000
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	34000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	34000	usd
CY2023Q4	fil	Due To Related Parties DueToRelatedParties	28958	usd
CY2022Q4	fil	Due To Related Parties DueToRelatedParties	44882	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17325950	shares
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	59415	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	189582	usd
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17075950	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	150000	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.02
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	-1118000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.194
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	516000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.351
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	752000	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.251
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	-250000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.05
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	732000	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.227
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	270000	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.128
CY2023	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	166424	usd
CY2022	fil	Stock Based Compensation On Rsa S Vested StockBasedCompensationOnRsaSVested	181112	usd
CY2023Q4	fil	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	34500	usd
CY2023Q4	fil	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	34500	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	789000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	737300	usd
CY2023	fil	Deferred Tax Assets Accrued Payroll DeferredTaxAssetsAccruedPayroll	220000	usd
CY2022	fil	Deferred Tax Assets Accrued Payroll DeferredTaxAssetsAccruedPayroll	184300	usd
CY2023	fil	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	47300	usd
CY2022	fil	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	52000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1056300	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	973600	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-117800	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-93000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation IncomeTaxReconciliationNondeductibleExpenseDepreciation	-4700	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation IncomeTaxReconciliationNondeductibleExpenseDepreciation	-5600	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	200	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	200	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	34900	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	77800	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	35700	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	35700	usd
CY2023	fil	Excess Book Gain On Disposal Over Tax ExcessBookGainOnDisposalOverTax	0	usd
CY2022	fil	Excess Book Gain On Disposal Over Tax ExcessBookGainOnDisposalOverTax	-22100	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	51700	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3757000	usd
CY2023Q4	fil	Due To Related Parties1 DueToRelatedParties1	28958	usd
CY2022Q4	fil	Due To Related Parties1 DueToRelatedParties1	44882	usd
CY2023	fil	Company Officers Ownership Percentage CompanyOfficersOwnershipPercentage	43.2	pure
CY2022	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	165000	usd
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	225000	usd

Files In Submission

Name	View Source	Status
0001096906-24-001512-index-headers.html	Edgar Link	pending
0001096906-24-001512-index.html	Edgar Link	pending
0001096906-24-001512.txt	Edgar Link	pending
0001096906-24-001512-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fmhs-20231231.htm	Edgar Link	pending
fmhs-20231231.xsd	Edgar Link	pending
fmhs_ex31z1.htm	Edgar Link	pending
fmhs_ex31z2.htm	Edgar Link	pending
fmhs_ex32z1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
fmhs-20231231_cal.xml	Edgar Link	unprocessable
fmhs-20231231_def.xml	Edgar Link	unprocessable
fmhs-20231231_lab.xml	Edgar Link	unprocessable
fmhs-20231231_pre.xml	Edgar Link	unprocessable
fmhs-20231231_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FMHS
FARMHOUSE, INC. /NV Stock $fmhs

2024 Q3 Form 10-K Financial Statement

#000109690624001512 Filed on July 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FMHS FARMHOUSE, INC. /NV Stock $fmhs

2024 Q3 Form 10-K Financial Statement

#000109690624001512 Filed on July 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FMHS
FARMHOUSE, INC. /NV Stock $fmhs